Invention Grant
- Patent Title: Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
-
Application No.: US16615040Application Date: 2018-05-30
-
Publication No.: US11414402B2Publication Date: 2022-08-16
- Inventor: Martin Lee Stockley , Mark Ian Kemp , Andrew Madin , Michael David Woodrow
- Applicant: MISSION THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee Address: GB Cambridge
- Priority: GB1708652 20170531
- International Application: PCT/GB2018/051454 WO 20180530
- International Announcement: WO2018/220355 WO 20181206
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D403/12 ; C07D207/14 ; C07D401/12 ; C07D401/14 ; C07D403/14 ; C07D498/04
Abstract:
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).
Public/Granted literature
- US20200172518A1 SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS Public/Granted day:2020-06-04
Information query
